Agenus Inc. (NASDAQ:AGEN – Free Report) – Stock analysts at HC Wainwright reduced their Q3 2026 earnings estimates for Agenus in a research note issued on Tuesday, August 11th. HC Wainwright analyst E. Bodnar now forecasts that the biotechnology company will earn ($0.01) per share for the quarter, down from their previous estimate of $0.05. HC Wainwright currently has a “Buy” rating and a $25.00 price target on the stock. The consensus estimate for Agenus’ current full-year earnings is ($0.17) per share. HC Wainwright also issued estimates for Agenus’ Q4 2026 earnings at ($0.04) EPS, FY2026 earnings at ($0.37) EPS, FY2027 earnings at ($0.43) EPS, FY2028 earnings at ($0.68) EPS, FY2029 earnings at ($0.71) EPS and FY2030 earnings at ($0.37) EPS.
A number of other equities research analysts also recently issued reports on AGEN. Zacks Research downgraded shares of Agenus from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 11th. Weiss Ratings upgraded Agenus from a “sell (d)” rating to a “sell (d+)” rating in a research note on Friday, August 7th. B. Riley Financial reissued a “buy” rating and set a $14.00 price target (up from $8.00) on shares of Agenus in a report on Thursday, July 30th. Finally, Wall Street Zen upgraded Agenus from a “buy” rating to a “strong-buy” rating in a research report on Sunday. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Agenus currently has a consensus rating of “Hold” and a consensus price target of $19.50.
Agenus Price Performance
Agenus stock opened at $6.90 on Thursday. The firm has a market cap of $310.64 million, a PE ratio of 2.67 and a beta of 1.41. The stock’s fifty day moving average price is $4.69 and its two-hundred day moving average price is $3.89. Agenus has a one year low of $2.71 and a one year high of $8.85.
Agenus (NASDAQ:AGEN – Get Free Report) last announced its earnings results on Friday, August 7th. The biotechnology company reported ($0.01) EPS for the quarter, missing the consensus estimate of $0.05 by ($0.06). Agenus had a negative return on equity of 45.12% and a net margin of 69.33%.The business had revenue of $34.52 million for the quarter, compared to the consensus estimate of $34.00 million.
Institutional Trading of Agenus
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Invesco Ltd. bought a new position in Agenus in the 1st quarter valued at approximately $88,000. AQR Capital Management LLC boosted its position in Agenus by 3,080.3% during the 1st quarter. AQR Capital Management LLC now owns 441,486 shares of the biotechnology company’s stock worth $664,000 after buying an additional 427,604 shares during the period. Acadian Asset Management LLC bought a new stake in Agenus during the 1st quarter worth approximately $58,000. JPMorgan Chase & Co. grew its holdings in Agenus by 608.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 78,637 shares of the biotechnology company’s stock worth $359,000 after acquiring an additional 67,530 shares during the last quarter. Finally, Marshall Wace LLP acquired a new position in Agenus in the 2nd quarter valued at approximately $1,976,000. 61.46% of the stock is currently owned by institutional investors.
Agenus News Summary
Here are the key news stories impacting Agenus this week:
- Positive Sentiment: HC Wainwright raised its Q3 2026 EPS forecast to $0.05 from $0.03, increased its Q4 forecast to $0.05 from $0.01, and improved its FY2026 loss estimate to $0.15 per share from $0.22. The firm maintained a Buy rating and a $25 price target for the Q3 update, while other notes cited a $30 target. These revisions suggest better near-term earnings expectations and may be supporting investor optimism.
- Positive Sentiment: Agenus expanded its board from six to seven members and appointed Rom… as a new director. The addition could strengthen the company’s governance and strategic oversight. Agenus Strengthens Board With New Director Appointment
- Neutral Sentiment: Reported short interest was listed at zero shares, with a zero-day days-to-cover ratio. Because the figures are internally inconsistent and show no measurable short position, they provide little reliable information about trading pressure.
- Negative Sentiment: HC Wainwright lowered its longer-term EPS forecasts for FY2027 through FY2030, including FY2027 to a $0.19 loss from $0.16, FY2028 to a $0.49 loss from $0.43, FY2029 to a $0.58 loss from $0.51, and FY2030 to a $0.31 loss from $0.26. The revisions indicate that profitability remains uncertain despite the improved 2026 outlook.
Agenus Company Profile
Agenus, Inc (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.
Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.
Featured Articles
- Five stocks we like better than Agenus
- GE Vernova’s AI Power Boom Faces a Profit Test
- Cardinal Health Earnings: Can Perfection Get Priced In Twice?
- Nebius’ Q2 Beat Shows the AI Bottleneck Is Capacity, Not Demand
- Legacy Jet Builders Stall While Embraer Accelerates to New Highs
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.
